One study stated that IL-4 can augment BCR-signalling and reduce the effectiveness of BCR-kinase inhibitors such as ibrutinib in CLL cells (Blunt et al. 2017). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.